EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
EyePoint, Inc. announced topline data from the LUGANO Phase 3 trial evaluating DURAVYU™ 2.7mg for wet age-related macular degeneration (wet AMD). DURAVYU demonstrated non-inferiority to on-label aflibercept in a key ad hoc analysis and achieved statistically significant superiority in reducing treatment burden by 42%. Key secondary endpoints, inclu…